Combination angiotensin receptor blocker-neutral endopeptidase inhibitor provides additive blood pressure reduction over angiotensin receptor blocker alone.
Bloch
Michael J
MJ
Department of Internal Medicine, University of Nevada School of Medicine, and Risk Reduction Center, Saint Mary's Regional Medical Center, 645 North Arlington Street, Reno, NV 89503, USA. mbloch@aol.com
Basile
Jan N
JN
D000613:Aminobutyrates / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D001794:Blood Pressure / Q000187:drug effects; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015260:Neprilysin / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use*; D012084:Renin-Angiotensin System / Q000187:drug effects*; D013777:Tetrazoles / Q000627:therapeutic use; D013841:Thiazepines / Q000627:therapeutic use*; D000068756:Valsartan
D000613:Aminobutyrates; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D004338:Drug Combinations; D011725:Pyridines; D013777:Tetrazoles; D013841:Thiazepines; C106266:omapatrilat; D000068756:Valsartan; D015260:Neprilysin; C549068:sacubitril and valsartan sodium hydrate drug combination